IMGN - ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA. The presentation is scheduled for August 10, 2023 at 10:00 am ET.
A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com . Following the live webcast, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727873886/en/
INVESTOR RELATIONS CONTACT
ImmunoGen
Anabel Chan
781-895-0600
anabel.chan@immunogen.com
MEDIA CONTACTS
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com